Trial Profile
An Open-label, Multi-center, Randomized Phase II Study of Fulvestrant Anastrozole Combination Versus Anastrozole Alone in Patients With Luminal A-like Postmenopausal Advanced Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 21 Oct 2015 Status changed from recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 03 Jul 2014 New trial record